Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials session at EuroPCR 2018, May 21-24 in Paris, France.

Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European Society of Cardiology (ESC) Heart Failure 2018 World Congress, May 26-29 in Vienna, Austria. William T. Abraham, M.D., professor of medicine, physiology and cell biology and director, Division of Cardiovascular Medicine at the Ohio State University presented the data.

ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and demonstrated a statistically significant reduction in blood pressure in hypertensive patients. In addition, the company announced submission of an investigational device exemption (IDE) supplement to the U.S. Food and Drug Administration (FDA) for a pivotal study of its Paradise System for the treatment of hypertension. Prof. Ajay Kirtane, M.D., of New York-Presbyterian Hospital/Columbia University has taken the role of co-principal investigator for RADIANCE-HTN.

May 29, 2018 — The first placebo-controlled trial that looked at how fractional flow reserve (FFR) and instantaneous ...

Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions. Bifurcation lesions account for approximately 20 percent of all percutaneous coronary interventions (PCI).[i] The Bifurcation Cohort, part of the RESOLUTE ONYX Post-Approval Study, will include patients with coronary artery disease (CAD) receiving the Resolute Onyx DES in sizes ranging from 2–5 mm in diameter.